FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 hours per response:

Estimated average burden hours per response:

OMB APPROVAL							
OMB Number: 3235-0104							
Expires:	December 31, 2014						
Estimated average burden							
hours per response:	0.5						

BRANDT ERIC (Me		2. Date of Event R Statement (Month/Day/Year)	equiring	3. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]						
(Last)	(First)	(Middle)	_ 05/21/2003		4. Relationship of Reporting Perso (Check all applicable)	()		5. If Amendment, Date of Original Filed (Month/Day/Year)		
(Street) (City)	(State)	(Zip)	-		X Director Officer (give title below)	10% Owner Other (spec below)	6.	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person		
			Table I - Noi	n-Derivat	tive Securities Beneficiall	y Owned				
1. Title of Security (Instr. 4)				2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		(D) or (Inst	4. Nature of Indirect Beneficial Ownership (Instr. 5)			
					re Securities Beneficially (ants, options, convertible					
		2. Date Exerc Expiration Da (Month/Day/Y	ite	3. Title and Amount of Securiti Derivative Security (Instr. 4)	es Underlying	4. Conversion or Exercise	Form: Direct	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
		Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	(D) or Indirect (I) (Instr. 5)			
Stock Option	on ⁽¹⁾		05/21/2003	05/20/2013	Common Stock	20,000	13.22	D		

Explanation of Responses:

1. Right to buy under 1996 Stock and Option Plan vesting in 16 equal quarterly installments from 05-21-2003.

Valerie L. Andrews, Attorney-In-

Fact

** Signature of Reporting Person Da

Date

05/22/2003

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

CONFIRMING STATEMENT of Signature Authority

This Statement confirms that the undersigned has authorized and designated Kenneth S. Boger, Valerie L. Andrews, Michelle O. Rosen and Anne L. Bruno, and each of them acting alone, to execute and file on behalf of the undersigned any and all Forms 3, 4 and 5 (including any amendments thereto) that the undersigned may be required to file with the United States Securities and Exchange Commission as a result of the undersigned's ownership of or transactions in securities of Vertex Pharmaceuticals Incorporated. The authority of Kenneth S. Boger, Valerie L. Andrews, Michelle O. Rosen and Anne L. Bruno under this Statement shall continue until the undersigned is no longer required to file Forms 3, 4 or 5 with regard to the undersigned's ownership of or transactions in securities of Vertex Pharmaceuticals Incorporated, unless earlier revoked in writing. The undersigned acknowledges that Kenneth S. Boger, Valerie L. Andrews, Michelle O. Rosen and Anne L. Bruno are not assuming, nor is Vertex Pharmaceuticals Incorporated assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Act of 1934.

This Statement supersedes and replaces any earlier dated Statement that the undersigned has executed.

By: /s/ Eric K. Brandt

Date: May 21, 2003